Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPA + megestrol acetate vs NEPA + dexamethasone for prevention of T-Dxd–induced nausea and vomiting in breast cancer
ChiCTR2600116296Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of trastuzumab deruxtecan, netupitant + palonosetron, megestrol and dexamethasone in breast cancer and chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoint: Complete response rate (CR) for CINV in first cycle (0–120 hours). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecannetupitant + palonosetronmegestroldexamethasone
03
Conditions
breast cancerchemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2600116296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116296.